TrialJournal of Alzheimer's disease : JAD2024

Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease.

Jack Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.